MHUA Meihua Medical Technologies Co., Ltd.: Company Value to Revenue

Official company branding of Meihua Medical (MHUA)

Full automation of packaging lines and injection molding machines enables MeihuaMed (MHUA) to maintain 24/7 production of massive batches of consumables. The EV/Sales multiple clearly demonstrates the balance between capital protection and asset yield, where 0.00 determines this specific parameter level. Stable demand for syringes generates a regular cash flow despite modest margins, while competent management maintains market positions amid moderate corporate control risks.

Meihua Medical Technologies (MHUA): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 12/20/2025

MHUA (Meihua Medical Technologies): analytical breakdowns and indicator data

- company stock capitalization data:
Initial company analysis:MeihuaMed
Manufactured products of Meihua Medical Technologies Co., Ltd.

The implementation of eco-friendly polymers and the reduction of energy costs at MeihuaMed (MHUA) directly impact the manufacturer's operational efficiency and capitalization. By analyzing the EV/Revenue multiple, an investor assesses the total enterprise value, including net debt, relative to sales volume, which allows them to filter out speculative noise and determine the asset's fair value within a long-term investment class.

Competitor analysis for MeihuaMed

ISRG - EV/Sales Multiple|DHR: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple BD (BDX)|Enterprise Value-to-Revenue Ratio STERIS plc|Company Value to Revenue Ratio WST (West Pharmaceutical Services)|Company Value to Revenue BAX (Baxter Corp)|Masimo - Company Value to Revenue Ratio|Stevanato Group S.p.A. - Company Value to Revenue|Total Company Value-to-Revenue Ratio Teleflex Inc (TFX)|MMSI - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio Envista Holdings Corp NVST|ICUI: EV/Sales Multiple|Company Value to Revenue Ratio XRAY|LMAT (LeMaitre Corp) - EV/Sales Multiple|ATRC (AtriCure Inc) - Enterprise Value-to-Revenue Coefficient|EV/Sales Multiple STAA|NAGE (ChromaDex Corp) - Business Value to Revenue|ZimVie Inc. - Company Value to Revenue|Total Company Value-to-Revenue Ratio angiodynamics.com (ANGO)|CERS - Enterprise Value-to-Revenue Ratio|TKNO - EV/Sales Multiple|Monogram Technologies Inc (MGRM) - Enterprise Value-to-Revenue Ratio|STSS - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio InfuSystem Holdings, Inc.|Enterprise Value-to-Revenue Multiple Utah Medical Products UTMD|EV/Sales Multiple KRMD|Total Company Value-to-Revenue Ratio Nyxoah, S.A.|Microbot Medical Inc - Company Value to Revenue|Total Company Value-to-Revenue Ratio Pro-Dex Inc. (PDEX)|Zentek - EV/Sales Multiple|Elutia (ELUT) - Company Value to Revenue|Milestone Scientific Inc (MLSS) - Enterprise Value-to-Revenue Ratio|NXGL - Total Company Value-to-Revenue Ratio|Company Value to Revenue RVP|Harvard Bioscience, Inc. (HBIO) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple FEMY|Predictive Oncology Inc. - Company Value to Revenue Ratio|EV/Sales Multiple CJMB (Callan JMB Inc)|EV/Sales Multiple Atrion Corp ATRI|NeuroMetrix Corporation - EV/Sales Multiple